Cytokinetics, Incorporated

Stocks

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 21:00:00 13/07/2026 BST			5-day change	1st Jan Change
82.24 ^USD	-3.10%		-3.89%	+29.43%

07-07	RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating	MT
07-02	Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing	MT

Transcript : Cytokinetics, Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 09

Published on 06/09/2026 at 08:52 am BST - Modified on 06/12/2026 at 06:51 pm BST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Kyuwon Choi (Analysts)

Thank you for joining us. We'll continue with the next session. I'm Paul Choi, and I cover the SMID-cap biotech sector here at the firm. It's our pleasure to

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Cytokinetics, Incorporated

07-07	RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating	MT
07-02	Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing	MT
06-29	Cytokinetics Insider Sold Shares Worth $266,390, According to a Recent SEC Filing	MT
06-29	Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says	MT
06-29	UBS Upgrades Cytokinetics to Buy From Neutral, Adjusts Price Target to $115 From $69	MT
06-29	Analyst recommendations: Adobe, Palantir, Roblox, Micron, Salesforce…
06-21	Certain Options of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 21-JUN-2026.	CI
06-21	Certain Common Shares of Cytokinetics, Incorporated are subject to a Lock-Up Agreement Ending on 21-JUN-2026.	CI
06-16	Edgewise shares slip after heart-disease drug trial data disappoints investors	RE
06-09	Cytokinetics, Incorporated Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 09:18 AM
06-02	Cytokinetics Insider Sold Shares Worth $1,111,200, According to a Recent SEC Filing	MT
06-01	Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy	RE
06-01	Cytokinetics launches Myqorzo® (aficamten) in European Union, with first commercial availability in Germany	RE
06-01	Cytokinetics Launches Myqorzo in European Union with First Commercial Availability in Germany	CI
05-28	Cytokinetics Insider Sold Shares Worth $579,075, According to a Recent SEC Filing	MT